Files 14th Patent Application Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed a new non-provisional patent application in support of its ongoing drug candidate programs.
After what the company believes to be a favorable international search report of its May 2021 Patent Cooperation Treaty (“PCT”) application, the Company has filed a US non-provisional patent application claiming priority to the May 2021 PCT application.
The International Patent Searching authority has provided a written opinion supporting novelty, inventive steps and industrial applicability to multiple claims within Cybin’s patent filing. The Patent filing includes claims to compositions and methods to support certain elements of the company’s pre-clinical and research programs.
“Cybin’s portfolio now consists of 14 patent filings, 50+ proprietary molecules, 50+ pre-clinical studies, 4 active drug programs targeting major depressive disorder, alcohol use disorder, anxiety and therapy resistant psychiatric disorders. We continue to progress our IP portfolio across novel molecules, delivery mechanisms, processes and protocols as we continue to find new and novel discoveries through our pre-clinical findings thus expanding and strengthening IP,” stated Doug Drysdale, Chief Executive Officer.
About Cybin
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.